REMS
Absorption: Well absorbed following oral administration. Rectal absorption is variable. Intravenous administration results in complete bioavailability.
Distribution: Widely distributed. Crosses the placenta; enters breast milk in low concentrations.
Half-Life: Neonates: 7 hr; Infants and Children: 34 hr; Adults: 13 hr.
(analgesia and antipyresis)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 0.51 hr | 13 hr | 38 hr‡ |
Rect | 0.51 hr | 13 hr | 34 hr |
IV‡ | within 30 min | 30 min | 46 hr |
‡Depends on dose.
‡Antipyretic effects.
Contraindicated in:
Use Cautiously in:
CV: hypertension (IV), hypotension (IV)
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS, urticaria
F and E: hypokalemia (IV)
GI: ↑liver enzymes, constipation (↑ in children) (IV), HEPATOTOXICITY (WITH HIGHER DOSES), nausea (IV), vomiting (IV)
GU: renal failure (high doses/chronic use)
Hemat: neutropenia, pancytopenia
MS: muscle spasms (IV), trismus (IV)
Neuro: agitation (↑ in children) (IV), anxiety (IV), fatigue (IV), headache (IV), insomnia (IV)
Resp: atelectasis (↑ in children) (IV), dyspnea (IV)
Drug-drug:
Lab Test Considerations:
Toxicity and Overdose:
IV Administration: